Article Summary
王 婧,阿孜古丽·阿力木江,吐尔逊古丽·海木都拉,买买提·依斯热依力,陆 萍.地屈孕酮联合醋酸曲普瑞林用于子宫内膜异位症术后的临床效果[J].现代生物医学进展英文版,2019,19(20):3912-3915.
地屈孕酮联合醋酸曲普瑞林用于子宫内膜异位症术后的临床效果
Effect of Progesterone Combined with Triptorelin Acetate in the Treatment of Endometriosis after operation
Received:May 05, 2019  Revised:May 30, 2019
DOI:10.13241/j.cnki.pmb.2019.20.025
中文关键词: 地屈孕酮  曲普瑞林  子宫内膜异位症  术后  疗效
英文关键词: Progesterone  Triptorelin acetate  Endometriosis  Postoperative  Curative effect
基金项目:新疆维吾尔自治区自然科学基金项目(2018D01C134)
Author NameAffiliationE-mail
WANG Jing Gynecology and Obstetrics Department, People's Hospital of Xinjiang Uygur Autonomous Region, Uygur, Xinjiang, 830000, China wangjing198111@163.com 
A Zi-gu-li·A LI MU JIANG Gynecology and Obstetrics Department, People's Hospital of Xinjiang Uygur Autonomous Region, Uygur, Xinjiang, 830000, China  
Tu Er-xun-gu-li·HAI MU DU LA Gynecology and Obstetrics Department, People's Hospital of Xinjiang Uygur Autonomous Region, Uygur, Xinjiang, 830000, China  
MAI Mai-ti·YI SI RE NONG LI Gynecology and Obstetrics Department, People's Hospital of Xinjiang Uygur Autonomous Region, Uygur, Xinjiang, 830000, China  
LU Ping Gynecology and Obstetrics Department, People's Hospital of Xinjiang Uygur Autonomous Region, Uygur, Xinjiang, 830000, China  
Hits: 845
Download times: 460
中文摘要:
      摘要 目的:研究地屈孕酮联合醋酸曲普瑞林用于子宫内膜异位症术后的临床效果。方法:选择2015年1月~2017年12月在我院接受腹腔镜手术治疗的398例子宫内膜异位症患者,根据患者入院的顺序编号,采用奇偶数法将其分为两组,每组各199例。对照组术后单纯口服地屈孕酮治疗,每次月经后的第2 d服用,1片/次,2次/d,共服用药6个月。观察组术后采用地屈孕酮联合醋酸曲普瑞林治疗,即肌肉注射醋酸曲普瑞林,3.75 mg/次,1次/月,共连续给药6次。比较两组的疗效、治疗前后血清学指标、痛经、盆腔痛及性交痛程度的变化。结果:治疗后,观察组的总有效率明显高于对照组(P<0.05);两组的血清黄体生成激素(Luteinizing hormone,LH)和促卵泡生成素(Follicle-stimulating hormone,FSH)水平均未明显改变(P>0.05),而血清雌二醇(Estradiol,E2)、糖类抗原125(Carbohydrate antigen,CA125)和血管内皮生长因子(Vascular endothelial growth factor,VEGF)水平均较治疗前明显降低(P<0.05),且观察组以上指标均明显低于对照组(P<0.05)。两组治疗后痛经、盆腔痛及性交痛积分均较治疗前明显降低(P<0.05),且观察组明显低于对照组(P<0.05)。结论:子宫内膜异位症术后采取地屈孕酮联合醋酸曲普瑞林具有显著的治疗效果,能有效缓解患者的疼痛症状,并改善血清学相关指标,从而有效改善子宫内膜异位症术后的临床效果。
英文摘要:
      ABSTRACT Objective: To analysis the clinical effect of progesterone combined with triptorelin acetate in the treatment of endometriosis. Methods: Selected 398 patients with endometriosis who were treated in our hospital from January 2015 to December 2017 were enrolled in the order of admission. They were divided into two groups according to the odd-even method, each group of 199 cases. The control group was given didrogesterone orally only after operation, one tablet per time, two times per day, for 6 months. The observation group was treated with desdrogesterone combined with triptorelin acetate after operation, i.e. intramuscular injection of triprillin acetate, 3.75 mg/time, once a month, for 6 consecutive times. The curative effect, serological index, dysmenorrhea, pelvic pain and degree of sexual intercourse pain before and after treatment were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the levels of luteinizing hormone (LH) and Follicle-stimulating hormone (FSH) did not change significantly in the two groups (P>0.05), while the levels of serum estradiol (E2), carbohydrate antigen 125 (Carbohydrate antigen, CA125) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment (P<0.05). The scores of dysmenorrhea, pelvic pain and sexual pain in the two groups were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). Conclusion: Postoperative treatment of endometriosis with dydrogesterone combined with triptorelin acetate has a significant therapeutic effect, and can effectively alleviate the pain symptoms of patients, improve serum related indicators, and effectively improve endometriosis.
View Full Text   View/Add Comment  Download reader
Close